TriangleDISEASE & TREATMENT SETTING
PADCEV EJFV: Bladder Cancer (neoadjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
Broader topic: Bladder Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- neoadjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after cystectomy as adjuvant treatment
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for PADCEV EJFV (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice